Genenta is a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors.

Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro environment.

Genenta’s lead product candidate, Temferon™, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance.

Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

News and events

Healthcare Talk by RCS Academy e Corriere della Sera

Speakers: Pierluigi Paracchi, CEO Genenta Science. Register here

21st May, Milan, Corriere della Sera Sala Buzzati (live streaming on corriere.it)

Il ruolo Strategico delle Biotecnologie per la Competitività del Paese.

Speaker: Pierluigi Paracchi, CEO Genenta Science. On. Giulio Centemero, Membro della VI Commissione Finanze See DetailsRegistration here

29th May at 10.30am, Rome, Montecitorio


Our proprietary cell-based platform
allows the controlled expression
of various cytokines
by tumor infiltrating monocytes (TEMs).
This enables the delivery of targeted and controlled treatment of any
TEMs-expressing tumors
while preventing systemic toxicities.


With an initial clinical focus
on solid tumors with major unmet needs, Genenta’s platform of
autologous oncology products,
led by Temferon
in Phase 1/2a in glioblastoma,
is advancing through preclinical
and clinical assessment.


Our Scientists bring a unique
blend of multi-disciplinary
competence, vast experience
in cell therapy a global vision
and a commensurate
track-record in the
forefront of therapies
and drug development.

Pin It on Pinterest